{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:36Z","timestamp":1791632256224,"version":"4.3.4"},"reference-count":73,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AA28050"],"award-info":[{"award-number":["AA28050"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AA27486"],"award-info":[{"award-number":["AA27486"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA57928"],"award-info":[{"award-number":["DA57928"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["31313"],"award-info":[{"award-number":["31313"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brain &amp; Behavior Research Foundation","award":["AA28050"],"award-info":[{"award-number":["AA28050"]}]},{"name":"Brain &amp; Behavior Research Foundation","award":["AA27486"],"award-info":[{"award-number":["AA27486"]}]},{"name":"Brain &amp; Behavior Research Foundation","award":["DA57928"],"award-info":[{"award-number":["DA57928"]}]},{"name":"Brain &amp; Behavior Research Foundation","award":["31313"],"award-info":[{"award-number":["31313"]}]},{"name":"Mayo Clinic Research Pipeline K2R Program","award":["AA28050"],"award-info":[{"award-number":["AA28050"]}]},{"name":"Mayo Clinic Research Pipeline K2R Program","award":["AA27486"],"award-info":[{"award-number":["AA27486"]}]},{"name":"Mayo Clinic Research Pipeline K2R Program","award":["DA57928"],"award-info":[{"award-number":["DA57928"]}]},{"name":"Mayo Clinic Research Pipeline K2R Program","award":["31313"],"award-info":[{"award-number":["31313"]}]},{"name":"Terrance and Bette Noble Foundation","award":["AA28050"],"award-info":[{"award-number":["AA28050"]}]},{"name":"Terrance and Bette Noble Foundation","award":["AA27486"],"award-info":[{"award-number":["AA27486"]}]},{"name":"Terrance and Bette Noble Foundation","award":["DA57928"],"award-info":[{"award-number":["DA57928"]}]},{"name":"Terrance and Bette Noble Foundation","award":["31313"],"award-info":[{"award-number":["31313"]}]},{"name":"Mayo Clinic Center for Individualized Medicine","award":["AA28050"],"award-info":[{"award-number":["AA28050"]}]},{"name":"Mayo Clinic Center for Individualized Medicine","award":["AA27486"],"award-info":[{"award-number":["AA27486"]}]},{"name":"Mayo Clinic Center for Individualized Medicine","award":["DA57928"],"award-info":[{"award-number":["DA57928"]}]},{"name":"Mayo Clinic Center for Individualized Medicine","award":["31313"],"award-info":[{"award-number":["31313"]}]},{"name":"Donna Giordano","award":["AA28050"],"award-info":[{"award-number":["AA28050"]}]},{"name":"Donna Giordano","award":["AA27486"],"award-info":[{"award-number":["AA27486"]}]},{"name":"Donna Giordano","award":["DA57928"],"award-info":[{"award-number":["DA57928"]}]},{"name":"Donna Giordano","award":["31313"],"award-info":[{"award-number":["31313"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Background\/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), which were originally developed for managing type 2 diabetes by enhancing insulin secretion and reducing appetite, have emerged as promising candidates in alcohol use disorder (AUD). These medications offer a dual mechanism of action that aligns with the multifaceted nature of addiction by targeting both peripheral metabolic and central reward pathways. This review focused on the current clinical trials and real-world evidence regarding the effects of GLP-1RAs as novel therapeutics for AUD. We also discussed early but encouraging results from clinical trials in AUD, observational and real-world evidence, safety profiles, psychiatric considerations, and future directions leading beyond GLP-1RAs. Methods: A comprehensive English-language literature search was conducted per PRISMA guidelines across PubMed, Medline, Google Scholar, Web of Science, and trial registries. Using targeted keywords, we identified relevant clinical and observational studies on GLP-1RAs for alcohol use disorder, excluding off-topic or non-English works and assessing all studies for eligibility. Results: Out of 1080 records identified, seven studies met the inclusion criteria. The findings from recent clinical trials, large-scale observational studies, and real-world evidence suggest that GLP-1RAs may significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations. Their central effect on reward processing, coupled with a generally favorable safety profile, supports their potential therapeutic role beyond metabolic disorders. Conclusions: Emerging evidence positions GLP-1RAs as a promising new pharmacologic approach for managing AUD. Ongoing and future research should prioritize larger, longer-duration randomized controlled trials that include diverse populations, with specific attention to treatment motivation, co-occurring psychiatric conditions, and long-term outcomes.<\/jats:p>","DOI":"10.3390\/brainsci15070702","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:42:06Z","timestamp":1751355726000},"page":"702","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-8086","authenticated-orcid":false,"given":"Tyler S.","family":"Oesterle","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Fen","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"112495","DOI":"10.1016\/j.drugalcdep.2024.112495","article-title":"The burden of alcohol and substance use disorders in adolescents and young adults","volume":"266","author":"Danpanichkul","year":"2025","journal-title":"Drug Alcohol Depend."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1111\/bph.15795","article-title":"Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study","volume":"179","author":"Ho","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1038\/s41380-020-0855-9","article-title":"TSPAN5 influences serotonin and kynurenine: Pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response","volume":"26","author":"Ho","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"146562","DOI":"10.1016\/j.brainres.2019.146562","article-title":"Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1","volume":"1727","author":"Jerlhag","year":"2020","journal-title":"Brain Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Aran\u00e4s, C., Edvardsson, C.E., Shevchouk, O.T., Zhang, Q., Witley, S., Blid Sk\u00f6ldheden, S., Zentveld, L., Vall\u00f6f, D., Tufvesson-Alm, M., and Jerlhag, E. (2023). Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. eBioMedicine, 93.","DOI":"10.1016\/j.ebiom.2023.104642"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_12","unstructured":"Litwack, G. (2022). Chapter Fifteen\u2014Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus. Vitamins and Hormones, Academic Press."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.cmet.2024.09.003","article-title":"GLP-1 programs the neurovascular landscape","volume":"36","author":"Chen","year":"2024","journal-title":"Cell Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107770","DOI":"10.1016\/j.phrs.2025.107770","article-title":"Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges","volume":"216","author":"Zhou","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113537","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1460863","article-title":"The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects","volume":"146","author":"Hui","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_20","unstructured":"Kalra, S. (2011, January 24\u201328). Change in Alcohol Consumption Following Liraglutide Initiation: A Real-Life Experience. Proceedings of the 71st American Diabetes Association Annual Meeting 2011, San Diego, CA, USA. Poster 1029."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults with Alcohol Use Disorder: A Randomized Clinical Trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/wps.20457","article-title":"Estimating treatment coverage for people with substance use disorders: An analysis of data from the World Mental Health Surveys","volume":"16","author":"Degenhardt","year":"2017","journal-title":"World Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-pharmtox-031323-115847","article-title":"Alcohol Use Disorder Treatment: Problems and Solutions","volume":"64","author":"Koob","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Rungby","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2024","journal-title":"Addiction"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"82","author":"Lahteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dong, S., and Sun, C. (2022). Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1032199"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2423385","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kornelius, E., Huang, J.Y., Lo, S.C., Huang, C.N., and Yang, Y.S. (2024). The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-75965-2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103029","DOI":"10.1016\/j.eclinm.2024.103029","article-title":"Suicide and suicide attempt in users of GLP-1 receptor agonists: A nationwide case-time-control study","volume":"80","author":"Bezin","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_32","first-page":"e250091","article-title":"Suicide and Self-Harm Events with GLP-1 Receptor Agonists in Adults with Diabetes or Obesity: A Systematic Review and Meta-Analysis","volume":"150","author":"Ebrahimi","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 Receptor Agonist Use and Risk of Suicide Death","volume":"184","author":"Ueda","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1111\/dom.15864","article-title":"Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database","volume":"26","author":"Kim","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neuroimage.2006.12.035","article-title":"Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans","volume":"35","author":"Pannacciulli","year":"2007","journal-title":"Neuroimage"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2021","journal-title":"JCI Insight"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","article-title":"Glucagon-like Peptide-1 and the Central\/Peripheral Nervous System: Crosstalk in Diabetes","volume":"28","author":"Muscogiuri","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2337\/dc15-2706","article-title":"Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects","volume":"39","author":"Eldor","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"Ghenciulescu","year":"2025","journal-title":"Nat. Ment. Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/13811118.2015.1004489","article-title":"The Association of Alcohol Use Disorders with Suicidal Ideation and Suicide Attempts in a Population-Based Sample with Mood Symptoms","volume":"20","author":"Sung","year":"2016","journal-title":"Arch. Suicide Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cook, S., Osborn, D., Mathur, R., Forbes, H., Parekh, R., Maini, A., Neves, A.L., Gnani, S., Beaney, T., and Walters, K. (2024). Is alcohol use disorder associated with higher rates of depression and anxiety among people with new onset type 2 diabetes? A cohort study using linked primary care data in England. BMC Prim. Care, 25.","DOI":"10.1186\/s12875-024-02628-6"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/acer.14233","article-title":"Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice","volume":"44","author":"Litten","year":"2020","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2017.03.006","article-title":"Addictions Neuroclinical Assessment: A reverse translational approach","volume":"122","author":"Kwako","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/acer.13093","article-title":"Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development","volume":"40","author":"Litten","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/FPC.0b013e32835001c9","article-title":"Merging pharmacometabolomics with pharmacogenomics using \u20181000 Genomes\u2019 single-nucleotide polymorphism imputation: Selective serotonin reuptake inhibitor response pharmacogenomics","volume":"22","author":"Abo","year":"2012","journal-title":"Pharmacogenetics Genom."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7326\/0003-4819-145-10-200611210-00007","article-title":"Pharmacogenomics: Challenges and opportunities","volume":"145","author":"Roden","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FPC.0b013e32833d7b45","article-title":"Genome-wide association studies in pharmacogenomics: Successes and lessons","volume":"23","author":"Jorgenson","year":"2013","journal-title":"Pharmacogenetics Genom."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"153ps118","DOI":"10.1126\/scitranslmed.3003471","article-title":"Pharmacogenomics and patient care: One size does not fit all","volume":"4","author":"Giacomini","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102920","DOI":"10.1016\/j.eclinm.2024.102920","article-title":"Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: A systematic review","volume":"78","author":"Subhani","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCRESAHA.119.315209","article-title":"Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies","volume":"125","author":"Wu","year":"2019","journal-title":"Circ. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.neuron.2018.10.033","article-title":"Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons","volume":"100","author":"Engle","year":"2018","journal-title":"Neuron"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41398-024-02880-5","article-title":"Molecular mechanisms involved in alcohol craving, IRF3, and endoplasmic reticulum stress: A multi-omics study","volume":"14","author":"Ho","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"101798","DOI":"10.1016\/j.molmet.2023.101798","article-title":"Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation","volume":"77","author":"Ho","year":"2023","journal-title":"Mol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41380-022-01837-8","article-title":"Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder","volume":"29","author":"Ho","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41380-019-0377-5","article-title":"Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons","volume":"24","author":"Vadodaria","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41398-019-0426-5","article-title":"Alcohol-responsive genes identified in human iPSC-derived neural cultures","volume":"9","author":"Jensen","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"10965","DOI":"10.1038\/ncomms10965","article-title":"The TLX-miR-219 cascade regulates neural stem cell proliferation in neurodevelopment and schizophrenia iPSC model","volume":"7","author":"Murai","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1111\/acer.14414","article-title":"Gabapentin Enacarbil Extended-Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial","volume":"44","author":"Laska","year":"2020","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41398-022-01959-1","article-title":"Multi-omics signatures of alcohol use disorder in the dorsal and ventral striatum","volume":"12","author":"Zillich","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1093\/nar\/gkw166","article-title":"NetDecoder: A network biology platform that decodes context-specific biological networks and gene activities","volume":"44","author":"Ung","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zhang, C., Correia, C., Weiskittel, T.M., Tan, S.H., Meng-Lin, K., Yu, G.T., Yao, J., Yeo, K.S., Zhu, S., and Ung, C.Y. (2022). A Knowledge-Based Discovery Approach Couples Artificial Neural Networks with Weight Engineering to Uncover Immune-Related Processes Underpinning Clinical Traits of Breast Cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.920669"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/nar\/gkz417","article-title":"Regulostat Inferelator: A novel network biology platform to uncover molecular devices that predetermine cellular response phenotypes","volume":"47","author":"Ung","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ghanat Bari, M., Ung, C.Y., Zhang, C., Zhu, S., and Li, H. (2017). Machine Learning-Assisted Network Inference Approach to Identify a New Class of Genes that Coordinate the Functionality of Cancer Networks. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-07481-5"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.scr.2018.01.015","article-title":"Single-cell RNA sequencing reveals metallothionein heterogeneity during hESC differentiation to definitive endoderm","volume":"28","author":"Lu","year":"2018","journal-title":"Stem Cell Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"eaba1190","DOI":"10.1126\/sciadv.aba1190","article-title":"Diversification of reprogramming trajectories revealed by parallel single-cell transcriptome and chromatin accessibility sequencing","volume":"6","author":"Xing","year":"2020","journal-title":"Sci. Adv."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/7\/702\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:32Z","timestamp":1760032892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/7\/702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["brainsci15070702"],"URL":"https:\/\/doi.org\/10.3390\/brainsci15070702","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,29]]}}}